Atea Pharmaceuticals director proposes $27.2K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atea Pharmaceuticals, Inc. (AVIR) director Bruno Lucidi gave notice of a proposed sale of 6,741 common shares, with an aggregate market value of $27,189.82 and an approximate sale date of November 17, 2026. The shares were acquired from the issuer through a stock option exercise on November 17, 2026, with cash listed as the nature of payment.
Key Figures
Key Terms
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.